Eudaimonic Well-Being Tied to Ovarian Tumor Neuroeffector

This article originally appeared here.
Share this content:
Eudaimonic Well-Being Tied to Ovarian Tumor Neuroeffector
Eudaimonic Well-Being Tied to Ovarian Tumor Neuroeffector

TUESDAY, Sept. 29, 2015 (HealthDay News) -- Eudaimonic well-being is associated with lower tumor norepinephrine (NE) in women with epithelial ovarian cancer, according to a study published in the Oct. 1 issue of Cancer.

Lauren Z. Davis, from the University of Iowa in Iowa City, and colleagues assessed how two different aspects of well-being (eudaimonic and positive affect) and psychological distress were associated with tumor NE in 365 patients with ovarian cancer. High-performance liquid chromatography with electrochemical detection was used to measure tumor NE in frozen tissue samples.

The researchers found that eudaimonic well-being, positive affect, and psychological distress modeled as distinct, but correlated constructs. A good model fit was found for structural equation modeling analysis that included physical well-being, stage of disease, histology, psychological treatment history, beta-blocker use, and caffeine use as covariates. This model demonstrated that eudaimonic well-being was related to lower tumor NE (P = 0.045), while no effects were found for positive affect or psychological distress.

"Because adrenergic signaling is implicated in tumor progression, increasing eudaimonic well-being may improve both psychological and physiologic resilience in patients with ovarian cancer," the authors write.

Two authors disclosed financial ties to the medical device industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »